The Indian Council of Medical Research (ICMR) has licensed three indigenously developed biomedical technologies to leading Indian pharmaceutical and vaccine manufacturers for development, manufacturing and commercialisation. The move marks a significant step in translating publicly funded research into affordable healthcare solutions while strengthening India’s biomedical innovation ecosystem. Under the licensing agreements, Emcure Pharmaceuticals Ltd. and Biological E Ltd. will develop and commercialise these next-generation cancer therapeutics and vaccine technologies, reinforcing the country’s commitment to indigenous healthcare innovation.
ICMR Transfers Indigenous Biomedical Technologies
The technology transfer aims to accelerate the journey of laboratory research into commercially available healthcare products. By partnering with domestic pharmaceutical companies, ICMR seeks to make advanced therapies and vaccines more accessible while promoting self-reliance in biomedical research and manufacturing. The licensed technologies include SHetA2, a novel
anti-human papillomavirus (HPV) therapeutic candidate for treating Cervical Intraepithelial Neoplasia (CIN), licensed to Emcure Pharmaceuticals Ltd., two next-generation vaccine technologies targeting enteric bacterial infections, developed by ICMR–National Institute of Research in Bacterial Infections (ICMR-NIRBI), Kolkata, and licensed to Biological E Ltd.
SHetA2 Offers a New Hope for Cervical Cancer Prevention
Among the licensed technologies, SHetA2 stands out as a first-in-class targeted therapeutic candidate designed to treat HPV-induced precancerous cervical lesions. The technology was jointly developed by Dr. Showket Hussain of ICMR–National Institute of Cancer Prevention and Research (ICMR-NICPR) and Dr. Doris M. Benbrook of the Stephenson Cancer Center, University of Oklahoma, USA. Unlike conventional therapies, SHetA2 selectively destroys HPV-induced precancerous and cervical cancer cells while preserving healthy tissues. Consequently, it has the potential to become a safe, affordable and minimally invasive treatment option for women at risk of developing cervical cancer.
Next-Generation Vaccines Target Major Enteric Infections
In addition to the cancer therapeutic, ICMR licensed two innovative vaccine technologies developed by researchers at ICMR-NIRBI, Kolkata. One technology features a fusion construct containing the Salmonella typhi outer membrane protein, making it a promising candidate for a next-generation typhoid vaccine. The second technology is a recombinant vaccine composition designed to provide broad protection against Salmonella typhi, Salmonella paratyphi and Shigella infections. By targeting multiple enteric bacterial pathogens, the vaccine could significantly improve protection against common gastrointestinal infections.
Strengthening India’s Indigenous Healthcare Innovation
These technology transfers highlight ICMR’s continued focus on fostering industry-academia collaboration and accelerating the commercialisation of indigenous biomedical innovations. Moreover, the partnerships with Emcure Pharmaceuticals and Biological E are expected to speed up product development, regulatory approvals and large-scale manufacturing, enabling faster access to innovative therapies and vaccines.
Boosting India’s Biomedical Ecosystem
The licensing of these three indigenous technologies represents another milestone in India’s efforts to build a robust biomedical innovation ecosystem. By combining scientific research with industry expertise, the initiative supports the development of affordable next-generation cancer therapeutics and vaccines while reducing dependence on imported technologies. As reported by sambadenglish.com, as India continues to strengthen its healthcare infrastructure, such collaborations are expected to play a crucial role in advancing cancer prevention, infectious disease control and the country’s vision of becoming a global hub for biomedical innovation.
